Kiersten is a scientist-investor focused on developing deep-tech platforms in the life sciences: where most companies use AI or engineering technologies to improve their therapeutic development. Kiersten serves on several boards including Creyon Bio, Totus Medicines, MycoWorks, Stemson, Pairwise (past), Blue River Technology (acquired), Vital Fields (acquired), amongst others. Kiersten also serves as a director on not-for-profit boards such as the Danforth Center for Plant Sciences and the Keystone Symposia SAB. Kiersten holds a PhD in molecular biology and genetics and an MBA in finance from the University of Alberta.